GSK's Votrient Clears ODAC Despite Outdated Trial, FDA Safety Concerns

FDA might not always demand that a new oncologic be compared to the current standard of care if its trial was conducted before that standard was established, Office of Oncology Drug Products Director Richard Pazdur said at an Oct. 5 advisory committee meeting